Q-omics provides the consensus-scored SNORA70J profile across patient tissues and cancer cell-line models. SNORA70J expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SNORA70J is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, SNORA70J RNA expression shows 6,304 significant gene co-expression associations, with the highest sampling consensus in KIRC. Together, these results highlight KIRP, COAD, and KIRC as cancer lineages where SNORA70J shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA70J — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA70J survival associations across molecular data types. SNORA70J RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA70J RNA expression–survival associations across cancer types. High SNORA70J expression shows unfavorable associations in KIRP, KIRC, MESO, LUAD and BRCA, but favorable associations in CESC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SNORA70J RNA expression.
This table summarizes SNORA70J tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA70J. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA70J shows higher tumor expression in COAD, HNSC, BLCA and LUSC. The COAD box plot shows higher SNORA70J RNA expression in tumor versus normal tissue (log2 FC = +0.478, t-test p < 0.001).
This table shows molecular features associated with SNORA70J in patient tissues and cancer cell lines. In patient samples, SNORA70J shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
